More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin

Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.

As part of the ROCKET AF trial, researchers from multiple institutions, including Harvard Medical School; Mount Sinai Medical Center; Janssen Research & Development; and Bayer HealthCare Pharmaceuticals, randomized 14,264 patients with nonvalvular AF to receive either or dose-adjusted .

Post-hoc analysis was performed on all patients while receiving study medication until 2 days after the last dose.

Results showed that GI bleeding events (upper, lower, rectal) occurred more frequently in patients receiving rivaroxaban (n=394) than warfarin (n=290). In addition, major and nonmajor, clinically relevant bleeding occurred more frequently with rivaroxaban use than warfarin use.

However, there were fewer fatal GI bleeds with rivaroxaban and the absolute fatality rate was very low.

This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Stroke risk high when anti-clotting drugs stopped

Apr 25, 2012

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

Recommended for you

Poor response to cholesterol drugs may indicate blocked arteries

Feb 26, 2015

If your "bad" cholesterol level stays the same or increases after you take statin drugs, you may have more blocked arteries than people whose levels drop, according to research in the American Heart Association journal Arteriosclerosis, Th ...

Review: more whole grains, less coronary heart disease

Feb 25, 2015

(HealthDay)—Higher dietary intake of whole grains may reduce the risk of coronary heart disease (CHD), according to a meta-analysis published in the March 1 issue of The American Journal of Cardiology.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.